论文部分内容阅读
目的 :为了探讨活化血小板标志物CD6 2P ,CD6 3的阳性表达率 ,反映体内血小板活化程度和血栓形成倾向 ,以及防治血栓的有效方法。方法 :应用流式细胞仪 (FCM )测定 5 0例正常人群 (对照组 )、80例有血栓倾向患者及其中 30例治疗后外周血CD6 2P ,CD6 3的阳性表达率。结果 :疾病组两者阳性表达率明显高于正常组(P <0 .0 0 1,P <0 .0 0 1) ;治疗组治疗前后的差值有非常显著意义 (P <0 .0 0 1,P <0 .0 0 1) ;治疗后的CD6 2P与对照组无显著差异 (P =0 .4 17) ,而CD6 3的差异仍有显著性 (P <0 .0 1)。结论 :血栓倾向患者血小板功能亢进是导致血栓的重要原因 ;抵克力得能显著抑制血小板活化。FCM是测定血小板活化既准确又可靠的方法。
OBJECTIVE: To investigate the positive expression rates of activated platelet markers CD6 2P and CD6 3, to reflect the degree of platelet activation in vivo and the tendency of thrombosis, and to provide an effective method of prevention and treatment of thrombus. Methods: The positive expression rates of CD6 2P and CD6 3 in peripheral blood of 50 normal controls (control group), 80 thrombosis-prone patients and 30 of them were determined by flow cytometry (FCM). Results: The positive rate of the two groups was significantly higher than that of the normal group (P <0.01, P <0.01). The difference between before and after treatment in the treatment group was significant (P <0. 0 0 1, P <0.01). There was no significant difference between the treated CD6 2P group and the control group (P = 0.41, 17), but the difference of CD6 3 was still significant (P <0.01). Conclusions: Thrombocytopenia is an important cause of thrombus in patients with thrombophilia. Tacrolimus can inhibit platelet activation significantly. FCM is a measure of platelet activation is both accurate and reliable method.